RAPGEF3: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of RAPGEF3. The page also collects GeneMedi's different modalities and formats products for RAPGEF3 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the RAPGEF3 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Introcelluar Protein.
Enables guanyl-nucleotide exchange factor activity and protein domain specific binding activity. Involved in several processes, including positive regulation of protein modification process; regulation of actin cytoskeleton organization; and regulation of syncytium formation by plasma membrane fusion. Located in filopodium; lamellipodium; and microvillus. Colocalizes with cortical actin cytoskeleton and plasma membrane. Biomarker of congestive heart failure. [provided by Alliance of Genome Resources, Apr 2022]
Target ID | GM-T52489 |
Target Name | RAPGEF3 |
Gene ID | 10411,223864,59326,703967,486591,101085387,535383,100050541 |
Gene Symbol and Synonyms | 2310016P22Rik,9330170P05Rik,bcm910,CAMP-GEFI,EPAC,EPAC1,HSU79275,RAPGEF3 |
Uniprot Accession | O95398,Q9Z1C8 |
Uniprot Entry Name | RPGF3_HUMAN,RPGF3_RAT |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000079337 |
Target Classification | N/A |
Pre-made anti-RAPGEF3 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-RAPGEF3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-RAPGEF3 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-RAPGEF3 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | Therapeutics Target antibody | Detail |
Recombinant multi-species RPGF3/ RAPGEF3/ CAMP-GEFI protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RAPGEF3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
RAPGEF3 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |